Cue Biopharma, Inc.
NASDAQ:CUEBiotechnology
+$0.38 today
- Market cap
- $102.43M
- Beta
- 2.53
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.06
Volume 0.21M
Average 0.74M
CUE Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Cue Biopharma, Inc.NASDAQ: CUE
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $5.18M (cash outflow) fell 57.8% year over year, behind the -51.9% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -20.5% a year.
Context
- Net income amounted to 96.9% of revenue in FY2025, down 341.1 pp from a year earlier.
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$83.4M (+213.5%) for the fiscal year ending Dec 2026, a step up from the -34.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$5.18M-426.7% QoQ
- Last fiscal yearDec 2025
- -$26.6M-34.6% YoY
- LTMMar 2026
- -$19.52M-51.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -57.8% | +26.3% | +84.1 pp |
| 1 year | -34.6% | +213.5% | +248.1 pp |
| 3-year CAGR | -20.5% | -7.3% | +13.3 pp |
| 5-year CAGR | +2.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (26.6M) USD
- Year-over-year change
- +34.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (26.6M) | +34.6% |
| FY2024 | 2024-12-31 | (40.67M) | +19.8% |
| FY2023 | 2023-12-31 | (50.73M) | +4.3% |
| FY2022 | 2022-12-31 | (53.01M) | -20.0% |
| FY2021 | 2021-12-31 | (44.16M) | — |
Net Income vs competitors
How CUE compares with its peers on the latest reported figures
- CUE's LTM Mar 2026 net income of $19.52M is the 5th largest of the 7 companies compared; the peer median is $30.87M.
- Its year-over-year change of -51.9% is the 6th highest of 7, against a peer median of +7.2%.
- Net income amounts to 59.6% of revenue for CUE, versus a peer median of 1070.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $107.79M | +391.1% | -58.2% | — | |
| LTM Mar 2026 | $60.96M | -388.6% | -1.9% | 18297.5% | |
| LTM Mar 2026 | $37.19M | -32.9% | -5.5% | — | |
| LTM Mar 2026 | $24.54M | +1.8% | -10.4% | 1070.2% | |
| LTM Mar 2026 | $19.52M | -51.9% | -20.5% | 59.6% | |
| LTM Mar 2026 | $19.06M | +36.2% | -28.9% | — | |
| LTM Mar 2026 | $12.72M | +12.6% | -31.8% | 899.5% | |
| Peer median (excluding CUE) | $30.87M | +7.2% | -19.7% | 1070.2% | |
Competitors are the stored peer set for CUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (44.16M) | (53.01M) | (50.73M) | (40.67M) | (26.6M) |
| Depreciation & Amortization | (1.78M) | 1.81M | 3.44M | 2.35M | 958K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.52M | 9.5M | 8.18M | 6.85M | 4.74M |
| Change in Working Capital | (4.39M) | 356K | (934K) | (4.93M) | (3.3M) |
| Accounts Receivables | (1.73M) | 3.09M | (1.64M) | 753K | (6.5M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 520.4K | 83K | 770K | (678K) | 1.13M |
| Other Working Capital | (3.18M) | (2.81M) | (63K) | (5M) | 2.08M |
| Other Non-Cash Items | (26.13K) | (454K) | 90K | 74K | 2.51M |
| Operating Cash Flow | (38.84M) | (41.81M) | (39.96M) | (36.33M) | (21.69M) |
| Capital Expenditures | (913.04K) | (171K) | 0 | (66K) | (177K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 40K |
| Purchases of Investments | 0 | (29.45M) | 0 | 0 | (16.5M) |
| Sales of Investments | 10M | 5M | 25M | 0 | 16.5M |
| Other Investing Activities | 21.55K | 6K | 2K | 98K | 212K |
| Investing Cash Flow | 9.11M | (24.61M) | 25M | 32K | 75K |
| Debt Repayment | 0 | 10M | (2M) | (4M) | (4.5M) |
| Common Stock Issued | 17.38M | 39.3M | 13.39M | 14.22M | 30.79M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.85M | 4.36M | 473K | 18K | 0 |
| Financing Cash Flow | 19.23M | 53.66M | 11.86M | 10.24M | 26.29M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (10.5M) | (12.76M) | (3.1M) | (26.05M) | 4.68M |
| Free Cash Flow | (39.75M) | (41.98M) | (39.96M) | (36.4M) | (21.86M) |
Cue Biopharma, Inc.
NASDAQ:CUE
Intrinsic Alpha fair value
Locked
Current Price
$14.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.